We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Reducing Beta-secretase Reverses Alzheimer's Disease in Model

By LabMedica International staff writers
Posted on 01 Mar 2018
Employing a complex series of mouse models, a team of neurological disease researchers showed that reducing the level of the enzyme beta-secretase (BACE1) could reverse the clinical symptoms of Alzheimer's disease (AD).

An important factor in the disease process in AD is the accumulation of amyloid beta (Abeta) protein. More...
To form Abeta, amyloid precursor protein (APP) must be cut by two enzymes, beta-secretase and gamma-secretase. Drugs to block the beta-secretase enzyme (BACE inhibitors) in theory would prevent the buildup of beta-amyloid and may help slow or stop Alzheimer's disease. However, results from studies on BACE inhibitors have raised the possibility that the drugs currently being investigated for the treatment of Alzheimer's may have significant side effects related to impaired motor coordination.

Since mice that completely lack BACE1 suffer severe neurodevelopmental defects, investigators at the Cleveland Clinic (OH, USA) examined the possibility that inhibiting BACE1 in adult animals might be less harmful. To this end, they generated a strain of mice that gradually lost this enzyme as they grew older.

The investigators crossed these mice with a strain that started to develop amyloid plaques and Alzheimer's disease when they were about 75 days old. They reported in the February 14, 2018, online edition of the Journal of Experimental Medicine that the resulting offspring also formed plaques at this age, even though their BACE1 levels were approximately 50% lower than normal. However, the plaques began to disappear as the mice aged and lost BACE1 activity, until, at 10 months of age, the mice had no plaques in their brains at all.

This reversal in amyloid deposition caused significant improvement in gliosis and neuritic dystrophy. Moreover, synaptic functions, as determined by long-term potentiation and contextual fear conditioning experiments, were significantly improved, correlating with the reversal of amyloid plaques.

"To our knowledge, this is the first observation of such a dramatic reversal of amyloid deposition in any study of Alzheimer's disease mouse models," said senior author Dr. Riqiang Yan, now professor of neuroscience at the University of Connecticut (Storrs, USA). "Our study provides genetic evidence that preformed amyloid deposition can be completely reversed after sequential and increased deletion of BACE1 in the adult. Our data show that BACE1 inhibitors have the potential to treat Alzheimer's disease patients without unwanted toxicity. Future studies should develop strategies to minimize the synaptic impairments arising from significant inhibition of BACE1 to achieve maximal and optimal benefits for Alzheimer's patients."

Related Links:
Cleveland Clinic
University of Connecticut


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
ESR Analyzer
TEST1 2.0
New
Blood Glucose Test Strip
AutoSense Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The advanced test enables early, definitive detection of respiratory infections and pneumonia in critically ill patients (Photo courtesy of Shutterstock)

Rapid Test Detects Early Signs of Pneumonia in Critically Ill Hospitalized Patients

Hospital-acquired infections (HAIs) remain a significant source of life-threatening illness in intensive care, demanding fast and accurate diagnosis to ensure effective treatment. Hospital-acquired pneumonia... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: Prof. Nicholas Schwab has found a biomarker that can predict treatment outcome of glatirameracetate in MS patients (Photo courtesy of Uni MS - M. Ibrahim)

Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients

Multiple sclerosis (MS) patients starting therapy often face a choice between interferon beta and glatiramer acetate, two equally established and well-tolerated first-line treatments. Until now, the decision... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.